Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)

◆英語タイトル:Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors -Pipeline Insights, 2015
◆商品コード:DIMRMOA5518
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:25以上
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥135,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s,“Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors. This report provides information on the therapeutic development based on the Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

【レポートの目次】

• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Overview
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Disease Associated
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Pipeline Therapeutics
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Therapeutics under Development by Companies
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors – Discontinued Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors by Therapy Area, 2015
• Number of Products under Development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Monotherapy Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Combination Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Route of Administration
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Stage and Route of Administration
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Molecule Type
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Stage and Molecule Type
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Therapeutics – Discontinued Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015

• Number of Products under Development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors by Therapy Area, 2015
• Number of Products under Development for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Monotherapy Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Combination Products
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Route of Administration
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Stage and Route of Administration
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Molecule Type
• Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors Assessment by Stage and Molecule Type

【レポートのキーワード】

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)(Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitors -Pipeline Insights, 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆